Compass Therapeutics, Inc. (CMPX) has a consensus analyst rating of Buy, based on 13 analysts covering the stock. Of those, 13 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for CMPX is $11.20, representing a +105.9% upside from the current price of $5.44. Price targets range from a low of $9.00 to a high of $15.00.
